Data Insights

Vudalimab by Xencor for Non-Small Cell Lung Cancer: Likelihood of Approval

Vudalimab is under clinical development by Xencor and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Vudalimab in Non-Small Cell Lung Cancer

Data Insights

XmAb-662 by Xencor for Metastatic Melanoma: Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Metastatic Melanoma

Data Insights

XmAb-662 by Xencor for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

Data Insights

XmAb-662 by Xencor for Metastatic Renal Cell Carcinoma: Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Metastatic Renal Cell Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Metastatic Renal Cell Carcinoma

Data Insights

XmAb-662 by Xencor for Metastatic Colorectal Cancer: Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Metastatic Colorectal Cancer

Data Insights

XmAb-662 by Xencor for Esophageal Cancer: Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Esophageal Cancer

Data Insights

XmAb-662 by Xencor for Non-Small Cell Lung Cancer: Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Non-Small Cell Lung Cancer

Data Insights

XmAb-662 by Xencor for Endometrial Cancer: Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Endometrial Cancer

Data Insights

XmAb-662 by Xencor for Solid Tumor: Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Solid Tumor

Data Insights

XmAb-662 by Xencor for Small-Cell Lung Cancer: Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Small-Cell Lung Cancer

Data Insights

Plamotamab by Xencor for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Plamotamab is under clinical development by Xencor and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Plamotamab in Diffuse Large B-Cell Lymphoma

Data Insights

XmAb-662 by Xencor for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

XmAb-662 by Xencor for Metastatic Breast Cancer: Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Metastatic Breast Cancer

Data Insights

XmAb-662 by Xencor for Gastric Cancer: Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Gastric Cancer

Data Insights

XmAb-662 by Xencor for Cervical Cancer: Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Cervical Cancer

Data Insights

XmAb-662 by Xencor for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Cutaneous Squamous Cell Carcinoma (cSCC)

Data Insights

XmAb-662 by Xencor for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

XmAb-564 by Xencor for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval

XmAb-564 is under clinical development by Xencor and currently in Phase I for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-564 in Plaque Psoriasis (Psoriasis Vulgaris)

Data Insights

XmAb-662 by Xencor for Epithelial Ovarian Cancer: Likelihood of Approval

XmAb-662 is under clinical development by Xencor and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Epithelial Ovarian Cancer

Data Insights

Plamotamab by Xencor for Non-Hodgkin Lymphoma: Likelihood of Approval

Plamotamab is under clinical development by Xencor and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Plamotamab in Non-Hodgkin Lymphoma